Poliomyelitis leading to large-scale trials in the then Belgian Congo and the vaccination of seven million children in Poland against serotypes PV1 and PV3 between 1958 and 1960. The second inactivated polio virus vaccine was developed in 1952 by Jonas Salk at the University of Pittsburgh, and announced to the world on 12 April 1955. The Salk vaccine, or inactivated poliovirus vaccine, is based on poliovirus grown in a type of monkey kidney tissue culture (vero cell line), which is chemically inactivated with formalin. After two doses of inactivated poliovirus vaccine (given by injection), 90 percent or more of individuals develop
Jonas Salk known the world over, Salk, in the public's eye, had a superstar aura. Airplane pilots would announce that he was on board and passengers would burst into applause. Hotels routinely would upgrade him into their penthouse suites. A meal at a restaurant inevitably meant an interruption from an admirer, and scientists approached him with drop-jawed wonder as though some of the stardust might rub off." For the most part, however, Salk was "appalled at the demands on the public figure he has become and resentful of what he considers to be the invasion of his privacy", wrote "The New York